Physician profile
Rusha Khanal
NPI 1033861919
$727.08
in general payments reported to CMS, 2019-2025
11 companies · $599 in 2025
The $599 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $128 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $150.00 | 2025 | Echelon Endopath |
| Celltrion USA INC. | $132.30 | 2025 | Zymfentra |
| Abbvie INC. | $112.73 | 2024-2025 | |
| Janssen Biotech, INC. | $107.07 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $93.12 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $40.87 | 2024 | Givlaari |
| Braintree Laboratories, INC. | $21.39 | 2024 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $19.09 | 2025 | Eohilia |
| Janssen Pharmaceuticals, INC | $17.81 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.25 | 2025 | Xifaxan |
| Ardelyx, INC. | $15.45 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rusha Khanal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.